Severe thrombocytopenia during Natalizumab therapy: A case report

Natalizumab (NTZ) is a humanized monoclonal antibody that targets alpha4-integrins reducing leukocytes trafficking across the blood brain barrier [9]. Although NTZ has an unquestionable efficacy on disease activity in relapsing-remitting Multiple Sclerosis (RRMS), its safety profile has been questioned. Progressive multifocal leukoencephalopathy is the most frightening adverse event during NTZ-treatment [10]. However other NTZ-induced side effects have been described, including haematological disorders, particularly frequent in the newborns after NTZ-exposure during pregnancy [5].

Source link

Related posts

Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study


DBS of the PSA and the VIM in essential tremor: A randomized, double-blind, crossover trial


Exciting News!!!


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy